{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2C9 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2C9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-07",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065698",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Miklós Poór",
"url": "https://questionsmedicales.fr/author/Mikl%C3%B3s%20Po%C3%B3r",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu."
}
},
{
"@type": "Person",
"name": "Jian-Ping Cai",
"url": "https://questionsmedicales.fr/author/Jian-Ping%20Cai",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Slávka Bodnárová",
"url": "https://questionsmedicales.fr/author/Sl%C3%A1vka%20Bodn%C3%A1rov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Eszter Fliszár-Nyúl",
"url": "https://questionsmedicales.fr/author/Eszter%20Flisz%C3%A1r-Ny%C3%BAl",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Jian Liu",
"url": "https://questionsmedicales.fr/author/Jian%20Liu",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Infection Control for Perioperative Ultrasonography and Echocardiography.",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/36123263",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.jvca.2022.08.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Infection Control in Dental Clinics: Prosthodontics Perspectives.",
"datePublished": "2022-09-01",
"url": "https://questionsmedicales.fr/article/37283004",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5005/jp-journals-10024-3305"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ensuring effective infection prevention and control in the community.",
"datePublished": "2023-04-26",
"url": "https://questionsmedicales.fr/article/37132541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7748/ns.2023.e12158"
}
},
{
"@type": "ScholarlyArticle",
"name": "Preprocedural mouthwashes for infection control in dentistry-an update.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37079156",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00784-023-04953-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Infection prevention and control in tertiary care hospitals of Bangladesh: results from WHO infection prevention and control assessment framework (IPCAF).",
"datePublished": "2022-10-06",
"url": "https://questionsmedicales.fr/article/36203207",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13756-022-01161-4"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"item": "https://questionsmedicales.fr/mesh/D065698"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2C9 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment identifier un inducteur du CYP2C9 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2C9 ?\nQuels signes indiquent une induction du CYP2C9 ?\nComment les interactions médicamenteuses sont-elles diagnostiquées ?\nQuels médicaments sont souvent des inducteurs du CYP2C9 ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Infection+Control#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?\nComment l'induction du CYP2C9 affecte-t-elle les médicaments ?\nQuels effets secondaires peuvent survenir ?\nLes symptômes varient-ils selon les patients ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Infection+Control#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment prévenir l'induction du CYP2C9 ?\nLes patients doivent-ils informer leur médecin des médicaments ?\nDes tests génétiques peuvent-ils aider à la prévention ?\nComment éduquer les patients sur les inducteurs ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Infection+Control#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?\nQuels médicaments peuvent être utilisés pour contrer l'induction ?\nComment surveiller l'efficacité du traitement ?\nQuels sont les risques d'un traitement inapproprié ?\nLes changements de traitement doivent-ils être rapides ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Infection+Control#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?\nComment l'induction affecte-t-elle la santé globale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme ?\nComment gérer les complications liées à l'induction ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Infection+Control#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels sont les principaux facteurs de risque d'induction ?\nLa génétique joue-t-elle un rôle dans l'induction ?\nLes habitudes alimentaires influencent-elles l'induction ?\nLes maladies hépatiques augmentent-elles le risque ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Infection+Control#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2C9 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des antécédents médicamenteux et des tests de métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2C9 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pharmacogénétique et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2C9 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2C9 peut être un signe."
}
},
{
"@type": "Question",
"name": "Comment les interactions médicamenteuses sont-elles diagnostiquées ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont diagnostiquées par l'examen des interactions dans les bases de données médicales."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent des inducteurs du CYP2C9 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et certains anticonvulsivants sont des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de sous-dosage des médicaments, comme une douleur persistante, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment l'induction du CYP2C9 affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire l'efficacité des médicaments, entraînant des symptômes de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires liés à un sous-dosage, comme des convulsions, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la génétique et des médicaments pris."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques comme une réponse insuffisante au traitement peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2C9 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses est essentiel."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils informer leur médecin des médicaments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin de tous les médicaments pris aide à prévenir les interactions."
}
},
{
"@type": "Question",
"name": "Des tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier les patients à risque d'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les médicaments inducteurs et leurs effets est cruciale pour la prévention."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie, comme une alimentation saine, peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être nécessaire d'augmenter la dose des médicaments affectés pour compenser."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent être utilisés pour contrer l'induction ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs du CYP2C9 peuvent être utilisés pour réduire l'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des tests réguliers des niveaux de médicaments dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un traitement inapproprié ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut entraîner des complications graves, comme des crises épileptiques."
}
},
{
"@type": "Question",
"name": "Les changements de traitement doivent-ils être rapides ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements doivent être faits prudemment pour éviter des effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des crises convulsives ou une résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle la santé globale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut compromettre la santé en rendant les traitements moins efficaces, aggravant les maladies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un ajustement approprié du traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques à long terme incluent des maladies chroniques dues à un traitement inefficace."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier et des ajustements de traitement basés sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments, l'alcool et des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans l'induction ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent influencer l'activité du CYP2C9 et son induction."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles l'induction ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires, comme la consommation de pamplemousse, peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques peuvent augmenter le risque d'induction du CYP2C9."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions entre médicaments peuvent augmenter le risque d'induction enzymatique."
}
}
]
}
]
}
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Ultrasound technology has revolutionized point-of-care diagnostics, decision-making, and the guidance of interventional procedures in Anesthesiology and Perioperative Medicine. Recent literature has h...
The aim of this article is to discuss the infection control measures with focus on those related to prosthodontic work....
The risk of transmission of several infectious microorganisms during dental procedures and the increased awareness and knowledge of infectious diseases have led to an increased attention to the import...
High standards of occupational safety and dental infection control must be applied by dental personnel for the safety of patients and dental healthcare workers. All reusable items (critical and semicr...
In prosthodontics, items potentially contaminated with patient's blood and saliva are transported between dental clinics and dental laboratories. Such fluids may contain microorganisms with high poten...
In prosthodontic practice, a strict infection prevention plan should be implemented to minimalize the risk of infectious diseases transmission among prosthodontists, dental office, dental laboratory p...
Managing community-acquired infections remains an ongoing challenge for community nursing teams. The coronavirus disease 2019 (COVID-19) pandemic meant that community nurses had to ensure they were us...
Aerosols and splatter are routinely generated in dental practice and can be contaminated by potentially harmful bacteria or viruses such as SARS-CoV-2. Therefore, preprocedural mouthwashes containing ...
Literature on preprocedural mouthwashes for reduction of bacterial or viral load in dental aerosols was searched and summarized....
Preprocedural mouthwashes, particularly those containing chlorhexidine digluconate (CHX), cetylpyridinium chloride (CPC), or essential oils (EO), can significantly reduce the bacterial load in dental ...
The use of preprocedural mouthwashes containing antiseptics can be recommended according to currently available data, but further studies are needed, particularly on the effects on other viruses besid...
Preprocedural mouthwashes containing antiseptics can serve as part of a bundle of measures for protection of dental personnel despite some remaining ambiguities and in view of potential risks and side...
Infection prevention and control (IPC) in healthcare settings is imperative for the safety of patients as well as healthcare providers. To measure current IPC activities, resources, and gaps at the fa...
Between September and December 2020, we assessed 11 tertiary-care hospitals across Bangladesh. We collected the information from IPC focal person and/or hospital administrator from each hospital using...
The overall median IPCAF score was 355.0 (IQR: 252.5-397.5) out of 800. The majority (73%) of hospitals scored as 'Basic' IPC level, while only 18% of hospitals were categorized as 'Intermediate'. Mos...
The majority of sampled tertiary care hospitals demonstrate inadequate IPC level to ensure the safety of healthcare workers, patients, and visitors. Quality improvement programs and feedback mechanism...
Effective infection prevention and control within health care settings requires collaboration and coordination between infection control and environmental management teams. However, the work systems o...
Surgical site infections (SSIs) affect around a third of patients undergoing surgeries worldwide, annually. It is heterogeneously distributed with a higher burden in low and middle-income countries. A...
This is a prospective study performed in two phases involving surgeons and their hospitals from Indian rural and semi-urban regions. In the first phase, a questionnaire was administered to surgeons en...
There was full compliance towards appropriate perioperative sterilisation practices and postoperative mop count practice at the represented hospitals. But prophylactic antimicrobials were continued in...
SSI prevention practices and protocols were in place in all the less-resourced hospitals surveyed. The SSI rates are comparable or lower than other LMIC settings. However, this is accompanied by poor ...
Special pathogens are broadly defined as highly transmissible organisms capable of causing severe disease in humans. Children's hospital healthcare personnel (HCP) should be prepared to identify patie...
Healthcare providers are vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of their close proximity to patients with coronavirus disease 2019. SARS-CoV-...
This article reviews the impact of some of the most recent changes in clinical care management in cystic fibrosis on infection prevention practice and advice for people with cystic fibrosis....
People with cystic fibrosis (CF) consistently highlight infection control as one of their major concerns. Infection prevention guidance and practice has facilitated successful decreases in rates of ma...
Recent changes in CF clinical care have implications that will lead to further evolution of infection control practice and advice....